Literature DB >> 14724140

Endothelin and vascular function in liver disease.

K Moore1.   

Abstract

The endothelins are a group of three related peptides with two receptor subtypes, ET(A) and ET(B). Following the discovery of endothelin 1 as a potent vasoconstrictor, there has been intense interest in the role of endothelin on vascular function in liver disease. Speculation on the role of endothelin in the pathogenesis of acute renal failure, including hepatorenal syndrome, has also been speculated.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14724140      PMCID： PMC1774918          DOI： 10.1136/gut.2003.024703

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  33 in total

1.  Endothelin, a potent peptide agonist in the liver.

Authors:  C R Gandhi; K Stephenson; M S Olson
Journal:  J Biol Chem       Date:  1990-10-15       Impact factor: 5.157

2.  Increased plasma endothelin levels in patients with liver cirrhosis.

Authors:  J Uemasu; H Matsumoto; H Kawasaki
Journal:  Nephron       Date:  1992       Impact factor: 2.847

Review 3.  Signal transduction in hepatic stellate cells.

Authors:  M Pinzani; F Marra; V Carloni
Journal:  Liver       Date:  1998-02

4.  Action of endothelins on hepatic stellate cells.

Authors:  N Kawada; T Kuroki; K Kobayashi; M Inoue; K Kaneda; K Decker
Journal:  J Gastroenterol       Date:  1995-12       Impact factor: 7.527

5.  Endothelin-1 stimulates contraction of rat glomerular mesangial cells and potentiates beta-adrenergic-mediated cyclic adenosine monophosphate accumulation.

Authors:  M S Simonson; M J Dunn
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

6.  The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. Possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus.

Authors:  N Kawada; T A Tran-Thi; H Klein; K Decker
Journal:  Eur J Biochem       Date:  1993-04-15

7.  Endothelin action in rat liver. Receptors, free Ca2+ oscillations, and activation of glycogenolysis.

Authors:  C Serradeil-Le Gal; C Jouneaux; A Sanchez-Bueno; D Raufaste; B Roche; A M Préaux; J P Maffrand; P H Cobbold; J Hanoune; S Lotersztajn
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

8.  Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome.

Authors:  K Moore; J Wendon; M Frazer; J Karani; R Williams; K Badr
Journal:  N Engl J Med       Date:  1992-12-17       Impact factor: 91.245

9.  Endothelin-3 like immunoreactivity in plasma of patients with cirrhosis of the liver.

Authors:  V Gülberg; A L Gerbes; A M Vollmar; G Paumgartner
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

10.  The effect of endothelin and its antagonist Bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver.

Authors:  J Reichen; A L Gerbes; M J Steiner; H Sägesser; M Clozel
Journal:  J Hepatol       Date:  1998-06       Impact factor: 25.083
View more
  14 in total

1.  Cre recombinase-regulated Endothelin1 transgenic mouse lines: novel tools for analysis of embryonic and adult disorders.

Authors:  Andre L P Tavares; David E Clouthier
Journal:  Dev Biol       Date:  2015-02-25       Impact factor: 3.582

Review 2.  Role of endothelin in systemic and portal resistance in cirrhosis.

Authors:  P W Angus
Journal:  Gut       Date:  2006-09       Impact factor: 23.059

Review 3.  Liver cirrhosis and arterial hypertension.

Authors:  Jens H Henriksen; Soren Moller
Journal:  World J Gastroenterol       Date:  2006-02-07       Impact factor: 5.742

4.  Hepatorenal syndrome.

Authors:  Charles K F Ng; Michael H M Chan; Morris H L Tai; Christopher W K Lam
Journal:  Clin Biochem Rev       Date:  2007-02

Review 5.  Hypertension and liver disease.

Authors:  Jens H Henriksen; Søren Møller
Journal:  Curr Hypertens Rep       Date:  2004-12       Impact factor: 5.369

6.  Hepatorenal syndrome: insights into the mechanisms of intra-abdominal hypertension.

Authors:  Yizhong Chang; Xiaolong Qi; Zhiwei Li; Fei Wang; Shenglan Wang; Zhaojie Zhang; Chaohui Xiao; Tongling Ding; Changqing Yang
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

7.  Modulation of vascular contraction via soluble guanylate cyclase signaling in a novel ex vivo method using rat precision-cut liver slices.

Authors:  Anouk Oldenburger; Gerald Birk; Marco Schlepütz; Andre Broermann; Birgit Stierstorfer; Steven S Pullen; Jörg F Rippmann
Journal:  Pharmacol Res Perspect       Date:  2021-05

8.  The association between clinical symptoms, laboratory findings and serum endothelin 1 concentrations, in cirrhotic patients with and without hepatopulmonary syndrome.

Authors:  Manouchehr Khoshbaten; Mohammad Rostami Nejad; Khalil Ansarin; Reza Fatemi; David Al Dulaimi; Faramarz Derakhshan; Nagmeh Jafarinia; Sophie Barford; Mohammad Reza Zali
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2012

9.  Surgical portosystemic shunts versus transjugular intrahepatic portosystemic shunt for variceal haemorrhage in people with cirrhosis.

Authors:  Martin Brand; Leanne Prodehl; Chikwendu J Ede
Journal:  Cochrane Database Syst Rev       Date:  2018-10-31

10.  Endothelin receptor antagonism improves glucose handling, dyslipidemia, and adipose tissue inflammation in obese mice.

Authors:  Osvaldo Rivera-Gonzalez; Natalie A Wilson; Laura E Coats; Erin B Taylor; Joshua S Speed
Journal:  Clin Sci (Lond)       Date:  2021-07-30       Impact factor: 6.876
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.